HC Wainwright & Co. : Can Fite Biofarma (CANF.US) rating was reaffirmed and adjusted from buy to buy, with a target price of $18.00.
Can Fite Biofarma Analyst Ratings
HC Wainwright & Co. Reiterates Buy on Can Fite Biofarma, Maintains $18 Price Target
Buy Rating Affirmed for Can-Fite BioPharma on IND Clearance and Positive Clinical Study Outlook
Buy Rating Affirmed for Can-Fite BioPharma Amidst Strategic Expansions and Positive Clinical Prospects
HC Wainwright & Co. Maintains Buy on Can Fite Biofarma, Lowers Price Target to $18
Can Fite Biofarma Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Gilead Sciences (GILD), Alkermes (ALKS) and Can-Fite BioPharma (CANF)
HC Wainwright & Co. Reiterates Buy on Can Fite Biofarma, Maintains $34 Price Target
HC Wainwright & Co. Reiterates Buy on Can Fite Biofarma, Maintains $34 Price Target
Can-Fite BioPharma (CANF) Gets a Buy From H.C. Wainwright
Analysts Conflicted on These Healthcare Names: Can-Fite BioPharma (CANF), CareDx (CDNA) and Evotec AG (EVO)
No Data